

**Corporate Office:**

Office No. 508-511, Sacred World, 5<sup>th</sup> Floor, Above Macdonald,  
Vitthal Rao Shivarkar Road, Wanowrie, Pune – 411040  
Email: enquiry@cian.co, cianhealthcare@yahoo.co.in  
Web: [www.cian.co](http://www.cian.co)

**Registered Office:**

Milkat No. 16431, Block No. 1 from South Side, C.S. No. 227/10 3B,  
Harpale Park, Opp. Berger Paint, Phursungi, Tal. Haveli, Dist. Pune - 412 308,  
(Maharashtra) INDIA. Tele-Fax.: +91-20-26982792

**Factory:**

Kh. No.: 248, Village Sisona, Bhagwanpur, Roorkee, Haridwar,  
Pin - 247 661. Uttarakhand, Tel.: 1332 235352

CIN: L24233PN2003PLC017563

To,  
BSE Limited – CRD  
P.J. Towers, Dalal Street,  
Fort, Mumbai-400001

**Date: 01/06/2023**

Script Code: 542678

**SUB: Submission of Revised Financials for March, 31 2023 of CIAN HEALTHCARE LIMITED.**

Dear Sir(s),

Pursuant to Regulation 33 of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015, we are pleased to submit the revised Audited Financials Results for the Half year/Year ended 31<sup>st</sup> March, 2023.

Earlier we have uploaded financials but at the time of uploading wrong attachment of P&L was made.

You are requested to take on record the revised Audited Financial Results along with Audit Report for your and record and disseminate the same for the information of investors.

Thanking You,  
Yours Faithfully,  
For **CIAN HEALTHCARE LIMITED**

**SURAJ SHRINIWAS ZANWAR**  
Managing Director  
DIN: 01304850

Encls: *Audited Financial Results and Audit Report.*





**Independent Auditor's Report on Half Yearly Financial results and year to date results of the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended;**

To,  
The Board of Directors of  
Cian Healthcare Limited

**Report on the Audit of the Standalone Financial Statements**

**Opinion**

We have audited the accompanying standalone financial results of Cian Healthcare Limited (hereinafter referred to as the "Company"), which comprises the Standalone Balance sheet as at 31<sup>st</sup> March 2023, the Standalone Statement of Profit and Loss, the Standalone Statement of Changes in Equity, the Standalone Statement of cash flows as at and for the year ended on that date ("standalone financial results"), attached herewith, being submitted by the company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ('Listing Regulations').

In our opinion and to the best of our information and according to the explanations given to us, the aforesaid standalone financial results:

- (i) are presented in accordance with the Regulation 33 of the Listing Regulation in this regard; and
- (ii) give a true and fair view in conformity with recognition and measurement principles laid down in the applicable accounting Standards prescribed under section 133 of the Act read with the rule 7 of the Companies (Accounts) Rules, 2014 and other accounting principles generally accepted in India, of the standalone state of affairs of the company as at March 31, 2023, the standalone profit, standalone changes in equity and its standalone cash flows for the year ended on that date.

**Basis for Opinion**

We conducted our audit of the standalone financial statements in accordance with the Standards on Auditing (SAs) specified under section 143(10) of the Act (SAs). Our responsibilities under those Standards are further described in the *Auditor's Responsibilities for the Audit of the Standalone Financial Statements* section of our report. We are independent of the company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India (ICAI) together with the independence requirements that are relevant to our audit of the standalone financial statements under the provisions of the Act and the Rules



made thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the ICAI's Code of Ethics. We believe that the audit evidence obtained by us is sufficient and appropriate to provide a basis for our audit opinion on the standalone financial statements.

### **Board of Directors Responsibility and those charged with Governance for the Standalone Financial Statements**

The Company's Board of Directors is responsible for the matters stated in section 134(5) of the Companies Act, 2013 ("the Act") with respect to the preparation of these standalone financial statements that give a true and fair view of the standalone financial position, standalone financial performance, change in equity and Standalone cash flows of the Company in accordance with the accounting principles generally accepted in India, including the Accounting Standards specified under section 133 of the Act. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the financial statement that give a true and fair view and are free from material misstatement, whether due to fraud or error.

### **Going Concern**

In preparing the financial statements, management is responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless management either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

Company's Board of Directors is also responsible for overseeing the company's financial reporting process of the Group.

### **Auditor's Responsibilities for the Audit of the Standalone Financial Statements**

Our objectives are to obtain reasonable assurance about whether the standalone financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these standalone financial statements.





As part of an audit in accordance with SAs, We exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- a. Identify and assess the risks of material misstatement of the Standalone Financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud of higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- b. Obtain an undertaking of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under section 143(1)(i) of the Act, We are also responsible for expressing our opinion on whether the company has adequate internal financial controls with reference to financial statements in place and the operating effectiveness of such controls.
- c. Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the management.
- d. Conclude on the appropriateness of Management's use of going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events and conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw an attention in our auditor's report to the related disclosures in the Standalone financial statements or if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our audit report. However future events or conditions may cause the Company to cease to continue as a going concern.
- e. Evaluate the overall presentation, structure and content of the standalone financial statements, including the disclosures, and whether the standalone financial statements represent the underlying transactions and events in a manner that achieves fair presentation.
- f. We communicate with those charged with governance of the Company and such other entities included in the standalone financial results of which we are the independent auditors regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit. We also provide those charged with governance with a statement that we have complied relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that



may reasonably be thought to bear on our independence, and where applicable, related safeguards.

- g. We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33(8) of the Listing Regulations, as amended, to the extent applicable.

#### Other Matters

- a. The standalone financial results include the result for the year ended March 31, 2023 being the balancing figure between the audited figures in respect of the full financial year and the published unaudited year to date figures upto half year ended 30<sup>th</sup> September 2022 which was subject to limited review by us.
- b. The standalone financial result dealt with by this report has been prepared for the express purpose of filing with stock exchanges on which company's shares are listed. These results are based on and should be read with the audited standalone financial statement of the company for the year ended March 31 2023 on which we issued an unmodified opinion vide our report dated 30<sup>th</sup> May 2023.

For Agarwal Mahesh K. & Co.  
Chartered Accountants

*Sunny Boundia*

CA Sunny Boundia

Partner

FRN: 008007C

Membership No. 164172

UDIN: - 23164172BGWORH1521

Place: - Pune

Date: - 30.05.2023



**CIAN HEALTHCARE LIMITED**  
**MILKAT NO.3339, BLOCK NO.1 FROM SOUTH SIDE,**  
**C.S.NO.227/2+3A,HARPALE PARK,OPP.BERGER PAINT**  
**PHURSUNGI, TAL. HAVELI,DIST. PUNE-412308**  
**CIN: L24233PN2003PLC017563**

**STATEMENT OF STANDALONE PROFIT AND LOSS FOR THE PERIOD ENDING ON MARCH 31, 2022**

Particulars	Note No.	For the year ended	For the year ended
		March 31, 2023	March 31, 2022
		Rs. (in Lakhs)	Rs. (in Lakhs)
<b>A CONTINUING OPERATIONS</b>			
1 Income from operations	22	6,756.13	6,410.29
2 Other income	23	53.81	47.06
3 <b>Total Income (1+2)</b>		<b>6,809.94</b>	<b>6,457.35</b>
4 <b>Expenses</b>			
(a) Cost of materials consumed	24.a	3,569.05	4,018.68
(b) Purchases of stock-in-trade	24.b	1,011.44	501.42
(c) Changes in inventories of finished goods, work-in-progress	24.c	-484.86	-695.80
(d) Other Operating Expenses	25	405.67	542.75
(d) Employee benefits expense	26	805.91	820.46
(e) Finance costs	27	418.45	513.87
(f) Depreciation and amortisation expense	12.A & 12.B	364.42	256.80
(g) Other expenses	28	603.14	729.90
<b>Total expenses</b>		<b>6,693.22</b>	<b>6,688.09</b>
5 <b>Profit / (Loss) before exceptional and extraordinary items and tax (3 - 4)</b>		<b>116.72</b>	<b>-230.74</b>
6 Exceptional items	29.a		
7 <b>Profit / (Loss) before extraordinary items and tax (5 ± 6)</b>		<b>116.72</b>	<b>-230.74</b>
8 Extraordinary items	29.b	-3.32	6.77
9 <b>Profit / (Loss) before tax (7 ± 8)</b>		<b>120.04</b>	<b>-237.52</b>
10 <b>Tax expense:</b>			
(a) Current tax expense for current year		20.04	-
(b) (Less): MAT credit (where applicable)		-	-
(c) Current tax expense relating to prior years		-	-
(d) Net current tax expense		20.04	-
(e) Deferred tax		-7.68	-9.94
		12.36	-9.94
11 <b>Profit / (Loss) from continuing operations (9 ± 10)</b>		<b>107.68</b>	<b>-227.58</b>
12 <b>Earnings per share (24995764 Shares of Rs. 10/- each):</b>			
(a) Basic			
(i) Continuing operations		0.43	-0.96
(ii) Total operations		0.43	-0.96
(b) Diluted			
(i) Continuing operations		0.43	-0.96
(ii) Total operations		0.43	-0.96

For and on behalf of Board of Directors  
Cian Healthcare Limited  
CIN:L24233PN2003PLC017563

Mr. Suraj Zanwar  
Managing Director  
DIN: 01304850

Place : Pune  
Date : 30/05/2023

**CIAN HEALTHCARE LTD**  
**MILKAT NO.3339, BLOCK NO.1 FROM SOUTH SIDE,**  
**C.S.NO.227/2+3A,HARPALE PARK,OPP.BERGER PAINT**  
**PHURSUNGI, TAL. HAVELI,DIST. PUNE-412308**  
**Company Identification Number : L24233PN2003PLC017563**  
**STATEMENT OF STANDALONE FINANCIAL RESULTS FOR THE PERIOD ENDED MARCH 31, 2023**

Particulars	(Rs. In Lakhs)	(Rs. In Lakhs)	(Rs. In Lakhs)	(Rs. In Lakhs)
	Half Year Ended	Half Year Ended	Year Ended	Year Ended
	31st March, 2023	30th September, 2022	31st March, 2023	31st March, 2022
	Audited	Unaudited	Audited	Audited
<b>A CONTINUING OPERATIONS</b>				
1 Income from operations	3,272.10	3,484.02	6,756.13	6,410.29
2 Other income	17.51	36.30	53.81	47.06
3 <b>Total Income (1+2)</b>	<b>3,289.61</b>	<b>3,520.33</b>	<b>6,809.94</b>	<b>6,457.35</b>
4 <b>Expenses</b>				
(a) Cost of materials consumed	1,566.48	2,002.57	3,569.05	4,018.68
(b) Purchases of stock-in-trade	346.65	664.79	1,011.44	501.42
(c) Changes in inventories of finished goods, work-in-progress	-130.05	-354.81	-484.86	-695.80
(d) Other Operating Expenses	191.06	214.60	405.67	542.75
(d) Employee benefits expense	404.63	401.29	805.91	820.46
(e) Finance costs	180.44	238.02	418.45	513.87
(f) Depreciation and amortisation expense	182.76	181.66	364.42	256.80
(g) Other expenses	374.57	228.57	603.14	729.90
<b>Total expenses</b>	<b>3,116.53</b>	<b>3,576.69</b>	<b>6,693.22</b>	<b>6,688.09</b>
5 <b>Profit / (Loss) before exceptional and extraordinary items and tax (3 - 4)</b>	<b>173.09</b>	<b>-56.36</b>	<b>116.72</b>	<b>-230.74</b>
6 Exceptional items		-	-	
7 <b>Profit / (Loss) before extraordinary items and tax (5 ± 6)</b>	<b>173.09</b>	<b>-56.36</b>	<b>116.72</b>	<b>-230.74</b>
8 Extraordinary items	1.16	-4.48	-3.32	6.77
9 <b>Profit / (Loss) before tax (7 ± 8)</b>	<b>171.93</b>	<b>-51.89</b>	<b>120.04</b>	<b>-237.52</b>
10 <b>Tax expense:</b>				
(a) Current tax expense for current year	20.04	-	20.04	-
(b) (Less): MAT credit (where applicable)		-	-	-
(c) Current tax expense relating to prior years		-	-	-
(d) Net current tax expense	20.04	-	20.04	-
(e) Deferred tax	16.96	-24.64	-7.68	-9.94
	<b>37.00</b>	<b>-24.64</b>	<b>12.36</b>	<b>-9.94</b>
11 <b>Profit / (Loss) from continuing operations (9 ±10)</b>	<b>134.93</b>	<b>-27.25</b>	<b>107.68</b>	<b>-227.58</b>
12 <b>Earnings per share (23360764 Shares of Rs. 10/- each):</b>				
(a) Basic				
(i) Continuing operations	0.54	-0.11	0.43	0.14
(ii) Total operations	0.54	-0.11	0.43	0.14
(b) Diluted	-	-	-	-
(i) Continuing operations	0.54	-0.11	0.43	0.14
(ii) Total operations	0.54	-0.11	0.43	0.14

For and on behalf of Board of Directors  
**CIAN HEALTHCARE LIMITED**  
**CIN:L24233PN2003PLC017563**

**Mr. Suraj Zanwar**  
**Managing Director**  
**DIN: 01304850**

**CIAN HEALTHCARE LIMITED**  
**MILKAT NO.3339, BLOCK NO.1 FROM SOUTH SIDE,**  
**C.S.NO.227/2+3A,HARPALE PARK,OPP.BERGER PAINT**  
**PHURSUNGI, TAL. HAVELI,DIST. PUNE-412308**  
**CIN: L24233PN2003PLC017563**

**STATEMENT OF STANDALONE BALANCE SHEET AS AT MARCH 31, 2023**

			(Rs. In Lakhs)	(Rs. In Lakhs)
	Note No.	As at March 31, 2023	As at March 31, 2022	
<b>A EQUITY AND LIABILITIES</b>				
<b>1 Shareholders' funds</b>				
(a) Share capital	3	2,499.58	2,499.58	
(b) Reserves and surplus	4	3,642.61	3,534.93	
(c) Money received against share warrants				
<b>2 Share application money pending allotment</b>				
<b>3 Non-current liabilities</b>				
(a) Long-term borrowings	5	1,289.93	1,999.24	
(b) Deferred tax liabilities (net)	30.11	110.17	117.85	
(c) Other long-term liabilities	6	631.17	57.30	
(d) Long-term provisions	7	90.63	82.49	
<b>4 Current liabilities</b>				
(a) Short-term borrowings	8	2,981.34	2,309.22	
(b) Trade payables	9			
(a) Total outstanding dues of micro enterprises and small enterprises		723.68	305.42	
(b) Total outstanding dues of creditors other than micro enterprises and small enterprises		1,638.99	2,573.88	
(c) Other current liabilities	10	401.45	465.47	
(d) Short-term provisions	11	53.72	32.90	
<b>TOTAL</b>		<b>14,063.28</b>	<b>13,978.28</b>	
<b>B ASSETS</b>				
<b>1 Non-current assets</b>				
(a) Property, Plant and equipment & Intangible Assets				
(i) Tangible Assets	12.A	2,941.85	3,282.09	
(ii) Capital work-in-progress	12.B	1,388.60	1,299.85	
(iii) Intangible assets under development				
(iv) Fixed assets held for sale				
(b) Non-current investments	13	708.84	708.84	
(c) Deferred tax assets (net)	30.11			
(d) Long-term loans and advances	14	1,081.53	1,410.29	
(e) Other non-current assets	15	1,118.47	397.92	
<b>2 Current assets</b>				
(a) Current investments	16	-	-	
(b) Inventories	17	3,480.99	3,401.69	
(c) Trade receivables	18	2,353.92	1,826.05	
(d) Cash and cash equivalents	19	112.57	122.27	
(e) Short-term loans and advances	20	442.26	451.89	
(f) Other current assets	21	434.24	1,077.39	
<b>TOTAL</b>		<b>14,063.28</b>	<b>13,978.28</b>	

**For and on behalf of Board of Directors**  
**Cian Healthcare Limited**  
**CIN:L24233PN2003PLC017563**

**Mr. Suraj Zanwar**  
Managing Director  
DIN: 01304850  
Date : 30/05/2023



**CIAN HEALTHCARE LIMITED**  
**MILKAT NO.3339, BLOCK NO.1 FROM SOUTH SIDE,**  
**C.S.NO.227/2+3A,HARPALE PARK,OPP.BERGER PAINT**  
**PHURSUNGI, TAL. HAVELI,DIST. PUNE-412308**  
**CIN: L24233PN2003PLC017563**

**STATEMENT OF STANDALONE CASHFLOW AS AT MARCH 31, 2023**

Particulars	As at March 31, 2023	As at March 31, 2022
<b>Cash Flow from operating activities</b>		
Net Profit after tax	107.68	-227.58
Adjustment for:		
- Depreciation and amortization expense	364.42	256.80
- Depreciation reserve written off	-	-3.29
- (Profit) / Loss on Sale/Disposal of assets	-	-
- Interest Expenses	408.08	476.14
- Interest & Dividend received	-4.56	-9.85
- Deferred Tax Liability	-7.68	-9.94
<b>Operating profit before working capital changes</b>	<b>867.95</b>	<b>482.29</b>
(Increase) / Decrease in Other Non Current asset	-720.55	149.92
(Increase) / Decrease in Inventories	-79.30	-830.76
(Increase) / Decrease in Trade receivables	-527.87	27.54
(Increase) / Decrease in Other Current Assets	643.14	-371.58
(Increase) / Decrease in Deferred Tax Asset	-	-
(Increase) / Decrease in other financial assets	9.64	-36.10
Increase / (Decrease) in Provisions	28.97	-24.75
Increase / (Decrease) in Trade Payables	-516.63	1,108.71
Increase / (Decrease) in Other Financial Liabilities/Short Term Borrowing	-	-
Increase / (Decrease) in Deferred tax liabilities	-	-
Increase / (Decrease) in Other Current Liabilities	-64.03	119.51
Increase / (Decrease) in Other Non Current Liabilities	573.87	-73.96
<b>Cash generated from operations</b>	<b>215.18</b>	<b>550.82</b>
Taxes paid		
<b>Net cash from operating activities</b>	<b>215.18</b>	<b>550.82</b>
<b>Cash flow from Investing activities</b>		
Purchase of fixed assets	-24.19	-1,665.43
Proceeds from sale of fixed assets/Subsidy	-	-
(Increase) / Decrease in Capital Work in Progress	-88.75	1,271.05
Interest & Dividend received	4.56	9.85
Purchases of Shares of Dr. Smiths Biotech Private Ltd.	-	-
Proceeds / (Repayment) of Other Financial Assets/Long Term Liabilities	-	-
<b>Net Cash flow from investing activities</b>	<b>-108.38</b>	<b>-384.53</b>
<b>Cash flow from financing activities</b>		
Proceeds from issuance of Share Capital including share premium	-	277.95
Proceeds from long term borrowings	-709.31	161.82
Proceeds / (Repayment) from / of short term borrowings (Above)	672.13	-813.39
Proceeds from Share Application Money	-	-
Dividend Paid including dividend distribution tax	-	-
Proceeds / (Repayment) for Other Financial Assets	328.76	584.80
Interest paid	-408.08	-476.14
<b>Net Cash flow from Financing Activities</b>	<b>-116.50</b>	<b>-264.96</b>
<b>Increase / (Decrease) in cash and cash equivalents</b>	<b>-9.70</b>	<b>-98.67</b>
Cash and cash equivalents at beginning of the year	122.27	220.95
<b>Cash and cash equivalents at end of the year</b>	<b>112.57</b>	<b>122.27</b>

**Notes :**

- i) The above Cash flow statement has been prepared under the indirect method set out in Accounting Standard-3, "Cash Flow Statement" notified under section 133 of the Companies Act 2013, read together with paragraph 7 of the Companies (Accounts) Rules 2014.
- ii) Details of Cash and cash equivalents are given in note No.2.04 and 2.05
- iii) Direct Tax paid is treated as arising from operating activities and are not bifurcated between investment and financing activities.
- iv) All figures in brackets/Negative indicate outflow.

As per our attached Report of even date

**For and on behalf of Board of Directors**  
**Cian Healthcare Limited**  
**CIN:L24233PN2003PLC017563**

**Mr. Suraj Zanwar**  
**Managing Director**  
**DIN: 01304850**

Place : Pune  
Date : 30/05/2023



**Independent Auditor's Report on Half Yearly Financial results and year to date results of the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended;**

To,  
The Board of Directors of  
Cian Healthcare Limited

### **Report on the Audit of the Consolidated Financial Statements**

#### **Opinion**

We have audited the accompanying consolidated financial results of Cian Healthcare Limited (hereinafter referred to as the "Holding Company") and its subsidiary (the Parent & Subsidiary referred to as the "Group"), which comprises the Consolidated Balance sheet as at 31<sup>st</sup> March 2023, the Consolidated Statement of Profit and Loss, the Consolidated Statement of Changes in Equity, the Consolidated Statement of cash flows as at and for the year ended on that date ("consolidated financial results"), attached herewith, being submitted by the Holding company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (' Listing Regulations').

In our opinion and to the best of our information and according to the explanations given to us, the aforesaid consolidated financial results:

- (i) Include the annual financial results of the following entities:

#### **Holding Company**

- Cian Healthcare Limited

#### **Subsidiary Company**

- Dr. Smiths Biotech Private Limited

- (ii) Is presented in accordance with the Regulation 33 of the Listing Regulation in this regard; and
- (iii) give a true and fair view in conformity with recognition and measurement principles laid down in the applicable accounting Standards prescribed under section 133 of the Act read with rule 7 of Companies (Accounts) Rules, 2014, and other accounting principles generally accepted in India, of the consolidated state of affairs of the Group as at March 31, 2023, the consolidated profit, consolidated changes in equity and its consolidated cash flows for the year ended on that date.



## **Basis for Opinion**

We conducted our audit of the consolidated financial statements in accordance with the Standards on Auditing (SAs) specified under section 143(10) of the Act (SAs). Our responsibilities under those Standards are further described in the *Auditor's Responsibilities for the Audit of the Consolidated Financial Statements* section of our report. We are independent of the Group in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India (ICAI) together with the independence requirements that are relevant to our audit of the consolidated financial statements under the provisions of the Act and the Rules made thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the ICAI's Code of Ethics. We believe that the audit evidence obtained by us and other auditor in terms of their reports referred to in "Other Matter" paragraph below, is sufficient and appropriate to provide a basis for our audit opinion on the consolidated financial statements.

## **Board of Directors Responsibility and those charged with Governance for the Consolidated Financial Statements**

The Company's Board of Directors is responsible for the matters stated in section 134(5) of the Companies Act, 2013 ("the Act") with respect to the preparation of these consolidated financial statements that give a true and fair view of the consolidated financial position, consolidated financial performance, change in equity and Consolidated cash flows of the Company in accordance with the accounting principles generally accepted in India, including the Accounting Standards specified under section 133 of the Act. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the financial statement that give a true and fair view and are free from material misstatement, whether due to fraud or error.

## **Going Concern**

In preparing the financial statements, management is responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless management either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

Company's Board of Directors is also responsible for overseeing the company's financial reporting process of the Group.





## Auditor's Responsibilities for the Audit of the Consolidated Financial Statements

Our objectives are to obtain reasonable assurance about whether the consolidated financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these consolidated financial statements.

As a part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- a. Identify and assess the risks of material misstatement of the Consolidated Financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- b. Obtain an undertaking of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under section 143(1)(i) of the Act, We are also responsible for expressing our opinion on whether the company has adequate internal financial controls with reference to financial statements in place and the operating effectiveness of such controls.
- c. Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the management.
- d. Conclude on the appropriateness of Management's use of going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events and conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the Consolidated financial statements or if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our audit report. However future events or conditions may cause the Company to cease to continue as a going concern.
- e. Evaluate the overall presentation, structure and content of the consolidated financial statements, including the disclosures, and whether the consolidated financial



statements represent the underlying transactions and events in a manner that achieves fair presentation.

- f. Obtain sufficient appropriate audit evidence regarding the financial results of the entities within the Group to express an opinion on the Consolidated Financial Results. We are responsible for the direction, supervision and performance of the audit of the financial information of such entities included in the consolidated financial results of which we are the independent auditors. For the other entity included in the consolidated financial results, which has been audited by other auditor, such other auditor remains responsible for the direction, supervision and performance of the audits carried out by them. We remain solely responsible for our audit opinion.
- g. We communicate with those charged with governance of the Holding Company and such other entities included in the consolidated financial results of which we are the independent auditors regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit. We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.
- h. We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33(8) of the Listing Regulations, as amended, to the extent applicable.

#### **Other Matters**

- a. The consolidated financial result includes audited financial results of one subsidiary named Dr.Smiths Biotech Private Limited, whose financial statement reflects total asset of Rs.2242.03 lakhs as at 31<sup>st</sup> March 2023, total income of Rs.2270.27 lakhs for the year ended 31<sup>st</sup> March 2023; total net profit after tax is Rs.95.26 lakhs for the year ended on that date. The financial statement of subsidiary has been audited by other auditor whose reports have been furnished to us by the management and our opinion and conclusion on the statement, in so far as it relates to the amounts and disclosure included in respect of the subsidiary, is based solely on the reports of the other auditor and the procedure performed by us as stated under Auditor's responsibility section above.

Our opinion on the consolidated financial results is not modified in respect of the above matter with respect to our reliance on the work done and the report of other auditor.





- b. The consolidated financial results also includes the Group's share of profit/loss after tax of Rs. 47.73 and Rs. 202.95 Lakhs for the half year ended 30<sup>th</sup> September 2022 and year ended 31<sup>st</sup> March 2023 respectively, as considered in the statement.
- c. The consolidated financial results include the result for the half year ended March 31, 2023 being the balancing figure between the audited figures in respect of the full financial year and the published unaudited year to date figures upto half year ended 30<sup>th</sup> September 2022 which was subject to limited review by us.
- d. The consolidated financial result dealt with by this report has been prepared for the express purpose of filing with stock exchanges on which company's shares are listed. These results are based on and should be read with the audited consolidated financial statement of the company for the year ended March 31 2023 on which we issued an unmodified opinion vide our report dated 30<sup>th</sup> May 2023.

**For Agarwal Mahesh K. & Co.**  
**Chartered Accountants**

*Sunny Boundia*



**CA Sunny Boundia**

**Partner**

**FRN: 008007C**

**Membership No. 164172**

**UDIN: - 23164172BGWORI6377**

**Place: - Pune**

**Date: - 30.05.2023**

**CIAN HEALTHCARE LIMITED**  
**MILKAT NO.3339, BLOCK NO.1 FROM SOUTH SIDE,**  
**C.S.NO.227/2+3A,HARPALE PARK,OPP.BERGER PAINT**  
**PHURSUNGI, TAL. HAVELI,DIST. PUNE-412308**  
**CIN: L24233PN2003PLC017563**

**STATEMENT OF CONSOLIDATED PROFIT AND LOSS FOR THE PERIOD ENDED ON MARCH 31, 2023**

Particulars	Note No.	(Rs. In Lakhs)	(Rs. In Lakhs)
		For the year ended March 31, 2023	For the Year Ended As at March 31, 2022
<b>A CONTINUING OPERATIONS</b>			
1 Income from operations	22	6,859.00	7,787.03
2 Other income	23	61.80	53.62
<b>3 Total Income (1+2)</b>		<b>6,920.80</b>	<b>7,840.65</b>
<b>4 Expenses</b>			
(a) Cost of materials consumed	24.a	2,636.63	4,966.11
(b) Purchases of stock-in-trade	24.b	1,012.25	512.45
(c) Changes in inventories of finished goods, work-in-progress	24.c	-304.82	-687.95
(d) Other Operating Expenses	25	591.66	756.97
(d) Employee benefits expense	26	940.50	985.60
(e) Finance costs	27	568.92	644.14
(f) Depreciation and amortisation expense	12.a & 12.b	543.13	427.49
(g) Other expenses	28	744.83	828.81
<b>Total expenses</b>		<b>6,733.10</b>	<b>8,433.63</b>
<b>5 Profit / (Loss) before exceptional and extraordinary items and tax (3 - 4)</b>		<b>187.70</b>	<b>-592.98</b>
6 Exceptional items	29.a		
<b>7 Profit / (Loss) before extraordinary items and tax (5 ± 6)</b>		<b>187.70</b>	<b>-592.98</b>
8 Extraordinary items	29.b	-11.38	7.33
<b>9 Profit / (Loss) before tax (7 ± 8)</b>		<b>199.08</b>	<b>-600.32</b>
<b>10 Tax expense:</b>			
(a) Current tax expense for current year		33.24	-
(b) (Less): MAT credit (where applicable)			
(c) Current tax expense relating to prior years			
(d) Net current tax expense		33.24	-
(e) Deferred tax		-37.11	-46.96
		-3.87	-46.96
<b>11 Profit / (Loss) from continuing operations (9 ± 10)</b>		<b>202.95</b>	<b>-553.36</b>
<b>12 Earnings per share (24995764 Shares of Rs. 10/- each):</b>			
(a) Basic		0.85	-2.21
(i) Continuing operations		0.85	-2.21
(ii) Total operations		0.85	-2.21
(b) Diluted		0.85	-2.21
(i) Continuing operations		0.85	-2.21
(ii) Total operations		0.85	-2.21

CIAN HEALTHCARE LTD  
MILKAT NO.3339, BLOCK NO.1 FROM SOUTH SIDE,  
C.S.NO.227/2+3A,HARPALE PARK,OPP.BERGER PAINT  
PHURSUNGI, TAL. HAVELI,DIST. PUNE-412308  
Company Identification Number : L24233PN2003PLC017563

STATEMENT OF CONSOLIDATED FINANCIAL RESULTS FOR THE HALF YEAR & YEAR ENDED MARCH 31, 2023

Particulars	(Rs. In Lakhs)		(Rs. In Lakhs)	
	Year Ended	Year Ended	Half Year Ended	Half Year Ended
	31st March, 2023	31st March, 2022	30th September 2022	31st March, 2023
	Audited	Audited	Unaudited	Audited
<b>A CONTINUING OPERATIONS</b>				
1 Income from operations	6,859.00	7,787.03	3,787.71	3,071.29
2 Other income	61.80	53.62	42.18	19.61
3 <b>Total Income (1+2)</b>	<b>6,920.80</b>	<b>7,840.65</b>	<b>3,829.89</b>	<b>3,090.91</b>
4 <b>Expenses</b>				
(a) Cost of materials consumed	2,636.63	4,966.11	1,752.52	884.11
(b) Purchases of stock-in-trade	1,012.25	512.45	664.89	347.36
(c) Changes in inventories of finished goods, work-in-progress	-304.82	-687.95	-241.34	-63.48
(d) Other Operating Expenses	591.66	756.97	316.41	275.24
(d) Employee benefits expense	940.50	985.60	467.17	473.33
(e) Finance costs	568.92	644.14	312.62	256.30
(f) Depreciation and amortisation expense	543.13	427.49	271.31	271.82
(g) Other expenses	744.83	828.81	279.81	465.02
<b>Total expenses</b>	<b>6,733.10</b>	<b>8,433.63</b>	<b>3,823.39</b>	<b>2,909.71</b>
5 <b>Profit / (Loss) before exceptional and extraordinary items and tax (3 - 4)</b>	<b>187.70</b>	<b>-592.98</b>	<b>6.50</b>	<b>181.20</b>
6 Exceptional items				
7 <b>Profit / (Loss) before extraordinary items and tax (5 ± 6)</b>	<b>187.70</b>	<b>-592.98</b>	<b>6.50</b>	<b>181.20</b>
8 Extraordinary items	-11.38	7.33	-11.66	0.28
9 <b>Profit / (Loss) before tax (7 ± 8)</b>	<b>199.08</b>	<b>-600.32</b>	<b>18.15</b>	<b>180.92</b>
10 <b>Tax expense:</b>				
(a) Current tax expense for current year	33.24	-	-	33.24
(b) (Less): MAT credit (where applicable)	-	-	-	-
(c) Current tax expense relating to prior years	-	-	-	-
(d) Net current tax expense	33.24	-	-	33.24
(e) Deferred tax	-37.11	-46.96	-29.58	-7.53
	<b>-3.87</b>	<b>-46.96</b>	<b>-29.58</b>	<b>25.71</b>
11 <b>Profit / (Loss) from continuing operations (9 ± 10)</b>	<b>202.95</b>	<b>-553.36</b>	<b>47.73</b>	<b>155.22</b>
12 <b>Earnings per share (23360764 Shares of Rs. 10/- each):</b>				
(a) Basic	0.85	-2.21	0.20	0.02
(i) Continuing operations	0.85	-2.21	0.20	0.02
(ii) Total operations	0.85	-2.21	0.20	0.02
(b) Diluted	0.85	-2.21	0.20	0.02
(i) Continuing operations	0.85	-2.21	0.20	0.02
(ii) Total operations	0.85	-2.21	0.20	0.02

For and on behalf of Board of Directors

CIAN HEALTHCARE LIMITED

CIN:L24233PN2003PLC017563

Mr. Suraj Zanwar

DIRECTOR

DIN: 01304850

**CIAN HEALTHCARE LIMITED**  
**MILKAT NO.3339, BLOCK NO.1 FROM SOUTH SIDE,**  
**C.S.NO.227/2+3A,HARPALE PARK,OPP.BERGER PAINT**  
**PHURSUNGI, TAL. HAVELI,DIST. PUNE-412308**  
**CIN: L24233PN2003PLC017563**

**STATEMENT OF CONSOLIDATED BALANCESHEET AS AT MARCH 31, 2023**

Particulars		Note No.	As at March 31 , 2023	As at March 31, 2022
<b>A</b>	<b>EQUITY AND LIABILITIES</b>			
	<b>1 Shareholders' funds</b>			
	(a) Share capital	3	2,499.58	2,499.58
	(b) Reserves and surplus	4	3,249.06	3,046.11
	(c) Money received against share warrants			
	<b>2 Share application money pending allotment</b>			
	<b>3 Non-current liabilities</b>			
	(a) Long-term borrowings	5	2,938.38	3,813.12
	(b) Deferred tax liabilities (net)	29	112.51	149.63
	(c) Other long-term liabilities	6	631.17	57.30
	(d) Long-term provisions	7	90.63	82.49
	<b>4 Current liabilities</b>			
	(a) Short-term borrowings	8	3,143.10	2,491.74
	(b) Trade payables	9		
	(a) Total outstanding dues of micro enterprises and small enterprises		836.13	511.65
	(b) Total outstanding dues of creditors other than micro enterprises and small enterprises		1,873.76	3,038.05
	(c) Other current liabilities	10	600.48	855.77
	(d) Short-term provisions	11	73.17	48.07
	<b>TOTAL</b>		<b>16,047.96</b>	<b>16,593.50</b>
<b>B</b>	<b>ASSETS</b>			
	<b>1 Non-current assets</b>			
	(a) Property, Plant and equipment & Intangible Assets			
	(i) Tangible Assets	12.A	4,458.51	4,957.91
	(iii) Capital work-in-progress	12.B	1,388.60	1,299.85
	(iv) Intangible assets under development			
	(v) Fixed assets held for sale			
	(b) Non-current investments	13	488.84	488.84
	(c) Deferred tax assets (net)	29		
	(d) Long-term loans and advances	14	1,069.18	1,443.14
	(e) Other non-current assets	15	1,218.47	507.93
	<b>2 Current assets</b>			
	(a) Current investments	16		
	(b) Inventories	17	3,664.35	3,937.16
	(c) Trade receivables	18	2,623.07	2,672.13
	(d) Cash and cash equivalents	19	132.96	134.15
	(e) Short-term loans and advances	20	569.22	755.12
	(f) Other current assets	21	434.75	397.26
	<b>TOTAL</b>		<b>16,047.96</b>	<b>16,593.50</b>

For and on behalf of Board of Directors  
**Cian Healthcare Limited**  
**CIN:L24233PN2003PLC017563**

**Mr. Suraj Zanwar**  
**Managing Director**  
**DIN: 01304850**

**CIAN HEALTHCARE LIMITED**  
**MILKAT NO.3339, BLOCK NO.1 FROM SOUTH SIDE,**  
**C.S.NO.227/2+3A,HARPALE PARK,OPP.BERGER PAINT**  
**PHURSUNGI, TAL. HAVELI,DIST. PUNE-412308**  
**CIN: L24233PN2003PLC017563**

**STATEMENT OF CONSOLIDATED CASHFLOW AS AT MARCH 31, 2023**

Particulars	As at March 31 , 2023	As at March 31, 2022
<b>Cash Flow from operating activities</b>		
Net Profit after tax	202.95	-553.36
Adjustment for:		
- Depreciation and amortization expense	543.13	427.49
- Depreciation reserve written off	-	-3.29
- (Profit) / Loss on Sale/Disposal of assets	-	-
- Interest Expenses	517.37	605.39
- Interest & Dividend received	-14.00	-16.06
- Deferred Tax Liability	-37.11	-46.96
<b>Operating profit before working capital changes</b>	<b>1,212.34</b>	<b>413.21</b>
(Increase) / Decrease in Other Non Current asset	-710.54	139.91
(Increase) / Decrease in Inventories	272.81	-864.66
(Increase) / Decrease in Trade receivables	49.06	-782.16
(Increase) / Decrease in Other Current Assets	-37.49	61.67
(Increase) / Decrease in Deferred Tax Asset		
(Increase) / Decrease in other financial assets	185.90	-72.44
Increase / (Decrease) in Provisions	33.25	-26.59
Increase / (Decrease) in Trade Payables	-839.82	1,492.42
Increase / (Decrease) in Other Financial Liabilities/Long Term Liabilities	573.87	-29.38
Increase / (Decrease) in Deferred tax liabilities	-	-
Increase / (Decrease) in Other Current Liabilities	-255.29	525.79
Increase / (Decrease) in Other Non Current Liabilities		
<b>Cash generated from operations</b>	<b>484.09</b>	<b>857.77</b>
Taxes paid		
<b>Net cash from operating activities</b>	<b>484.09</b>	<b>857.77</b>
<b>Cash flow from Investing activities</b>		
Purchase of fixed assets	-43.74	-1,731.77
Proceeds from sale of fixed assets/Subsidy		
(Increase) / Decrease in Capital Work in Progress	-88.75	1,293.57
Interest & Dividend received	14.00	16.06
Purchases of Shares of Dr. Smiths Biotech Private Ltd.	-	-
Proceeds / (Repayment) of Other Financial Assets/Long Term Liabilities	373.96	561.72
<b>Net Cash flow from investing activities</b>	<b>255.48</b>	<b>139.58</b>
<b>Cash flow from financing activities</b>		
Proceeds from issuance of Share Capital including share premium		277.95
Proceeds from long term borrowings	-874.75	49.08
Proceeds / (Repayment) from / of short term borrowings (Above)	651.36	-817.31
Proceeds from Share Application Money		
Dividend Paid including dividend distribution tax		
Proceeds / (Repayment) for Other Financial Assets		
Interest paid	-517.37	-605.40
<b>Net Cash flow from Financing Activities</b>	<b>-740.76</b>	<b>-1,095.68</b>
<b>Increase / (Decrease) in cash and cash equivalents</b>	<b>-1.19</b>	<b>-98.33</b>
Cash and cash equivalents at beginning of the year	134.15	232.47
<b>Cash and cash equivalents at end of the year</b>	<b>132.96</b>	<b>134.15</b>

**For and on behalf of Board of Directors**  
**Cian Healthcare Limited**  
**CIN:L24233PN2003PLC017563**

**Mr. Suraj Zanwar**  
**Managing Director**  
**DIN: 01304850**

Place : Pune  
Date : 30/05/2023





Date: - 30.05.2023

To  
Board of Directors  
Cian Healthcare Limited  
Pune

Dear Sirs,

**Sub: - Declaration pursuant to Regulation 33(3)(d) of SEBI (LODR) Regulations, 2015 as amended**

**DECLARATION**

It is hereby declared that we, Agarwal Mahesh K & Co., Chartered Accountants, have issued Audit Reports on Standalone and Consolidated audited financial results of the company for the Financial Year ended March 31, 2023 with unmodified opinion.

Kindly take the same on your record.

Warm Regards,

For Agarwal Mahesh K. & Co.  
Chartered Accountants

*Sunny Boundia*



CA Sunny Boundia  
Partner  
FRN No. - 008007C  
M.No. - 164172  
UDIN: 23164172BGWORI6377  
Pune



**Corporate Office:**

Office No. 508-511, Sacred World, 5<sup>th</sup> Floor, Above Macdonald,  
Vitthal Rao Shivarkar Road, Wanowrie, Pune – 411040  
Email: enquiry@cian.co, cianhealthcare@yahoo.co.in  
Web: [www.cian.co](http://www.cian.co)

**Registered Office:**

Milkat No. 16431, Block No. 1 from South Side, C.S. No. 227/10 3B,  
Harpale Park, Opp. Berger Paint, Phursungi, Tal. Haveli, Dist. Pune - 412 308,  
(Maharashtra) INDIA. Tele-Fax.: +91-20-26982792

**Factory:**

Kh. No.: 248, Village Sisona, Bhagwanpur, Roorkee, Haridwar,  
Pin - 247 661. Uttarakhand, Tel.: 1332 235352

**CIN:** L24233PN2003PLC017563

**Date: 30/05/2023**

To,  
BSE Limited – CRD  
P.J. Towers, Dalal Street,  
Fort, Mumbai-400001

*Script Code: 542678*

**Subject: Declaration on Audited Financial Result in compliance with the Regulation 33 (3) (d) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.**

Dear Sir(s),

Pursuant to second proviso to the Regulation 33(3)(d) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, We, the Board of Directors of Cian Healthcare Limited, hereby declare that the Statutory Auditor of the Company, M/s. Agarwal Mahesh K. & Co, Chartered Accountant (FRN: 008007C) has issued the Audit Report with unmodified opinion on the Standalone and Consolidated Audited Financial Results of the Company for the half year and year ended 31<sup>st</sup> March, 2023.

Request you to please take the above details on record.

Thanking You,

Yours Faithfully,

**For CIAN HEALTHCARE LIMITED**

SURAJ  
SHRINIWAS  
ZANWAR

Digitally signed by SURAJ SHRINIWAS ZANWAR  
DN: c=IN, o=MA, ou=Shri,  
2.5.4.20=6813702964421464529035609541a89011729685  
0a2a115f19a7f72a, postalCode=412308, email=BLOCK NO 1  
MILKAT NO 16431 HARPALE PARK PHURSUNGI  
pin409001=8077a7e4b662488a815956386a4b983,  
serialNumber=0989579420086a09f952a2a6d7a8652a8  
136a02a8938a2a82a157a, ou=OTHERS, o=CIAN  
HEALTHCARE LIMITED, cn=SURAJ SHRINIWAS ZANWAR  
Date: 2023.05.30 20:47:54 +05'30'

**SURAJ SHRINIWAS ZANWAR  
MANAGING DIRECTOR  
DIN: 01304850**

